Celgene resubmits NDA for MS candidate ozanimod

Celgene said it resubmitted an NDA to FDA for ozanimod to treat relapsing forms of multiple sclerosis. The company submitted earlier this month an MAA to EMA for the selective S1PR1 and S1PR5 modulator.

Last year’s regulatory setback for ozanimod was one of several clinical and regulatory setbacks to weigh on Celgene Corp. (NASDAQ:CELG) over the past year and a half (see "Rocky Road"). ...